Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Kunpeng Wu; Yahua Li; Zongming Li; Zihe Zhou; Xiaoyong Ge; Yifan Li; Xinwei Han; Peng Chen; Kewei Ren

doi:10.3389/fonc.2023.1143578

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Front Oncol. 2023 Sep 6:13:1143578. doi: 10.3389/fonc.2023.1143578. eCollection 2023.

Authors

Kunpeng Wu^{1

2

3}, Yahua Li^{1

2

3}, Zongming Li^{1

2

3}, Zihe Zhou^{1

2

3}, Xiaoyong Ge^{1

2

3}, Yifan Li^{1

2

3}, Xinwei Han^{1

2

3}, Peng Chen⁴, Kewei Ren^{1

2

3}

Affiliations

¹ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
² Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China.
³ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China.
⁴ Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Abstract

Purpose: This study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.

Material and methods: In this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).

Results: A total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment.

Conclusion: TACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable.

Keywords: TACE; comprehensive therapy; gastric or gastroesophageal junction cancer; immunotherapy; targeted therapy.